1. Executive Summary
• 1.1 Key Findings
• 1.2 Market Snapshot: Value, Volume, Capacity and Price, 2025 and 2034
• 1.3 Analyst Viewpoint
2. Research Methodology
• 2.1 Research Scope and Market Definition
• 2.2 Data Sources: Primary and Secondary Research
• 2.3 Market Sizing Approach: Bottom-Up Production and Consumption Model
• 2.4 Capacity Mapping and Utilization Estimation
• 2.5 Price Estimation by Excipient Chemistry
• 2.6 Forecasting Assumptions and Data Triangulation
• 2.7 Abbreviations and Units
3. Global Pharmaceutical Excipients Market Outlook
• 3.1 Market Value, 2021–2034 (US$ Billion)
• 3.2 Consumption Volume, 2021–2034 ('000 Tons)
• 3.3 Installed Production Capacity, 2021–2034 ('000 Tons)
• 3.4 Production Output and Capacity Utilization, 2021–2034
• 3.5 Average Selling Price Trend, 2021–2034 (US$ per Ton)
4. Market Dynamics
• 4.1 Drivers
• 4.1.1 Migration of Generic and Contract Formulation Volume to Asia
• 4.1.2 Growth of Biologics, Peptides and Long-Acting Injectables
• 4.1.3 Rising Share of Poorly Soluble Molecules in Development Pipelines
• 4.2 Restraints
• 4.2.1 Absence of a Standalone Regulatory Pathway for Novel Excipients
• 4.2.2 Energy and Raw Material Cost Inflation
• 4.3 Opportunities
• 4.3.1 Co-Processed and Ready-to-Use Excipient Systems
• 4.3.2 Regional Supply Localization near Formulation Clusters
• 4.3.3 Low-Carbon and Sustainably Documented Excipients
• 4.4 Challenges
• 4.4.1 Single-Site Supply Concentration and Business Continuity Risk
• 4.4.2 Supplier Requalification Cost and Time
5. Pricing and Cost Structure Analysis
• 5.1 Average Price by Excipient Chemistry, 2025 vs 2034
• 5.2 Cost Structure: Raw Materials, Energy, Compliance and Logistics
• 5.3 Price Pass-Through and Switching Cost Dynamics
• 5.4 Recent Supplier Price Adjustments
6. Production Capacity and Supply Resilience
• 6.1 Installed Capacity by Region, 2025 vs 2034
• 6.2 Capacity Additions and Planned Expansions Tracker
• 6.3 Supply Disruption Case Analysis
• 6.4 Multi-Site Qualification and Dual-Sourcing Assessment
7. Global Market Analysis by Product Type
• 7.1 Organic Chemicals
• 7.1.1 Carbohydrates (Sugars, Starches, Cellulose and Derivatives)
• 7.1.2 Petrochemicals (Glycols, Povidones, Acrylic Polymers, Mineral Hydrocarbons)
• 7.1.3 Oleochemicals (Fatty Alcohols, Glycerin, Lipids)
• 7.1.4 Proteins (Gelatin and Others)
• 7.2 Inorganic Chemicals
• 7.2.1 Calcium Phosphates
• 7.2.2 Metal Oxides
• 7.2.3 Calcium Carbonate
• 7.2.4 Silicates
• 7.2.5 Halites
8. Global Market Analysis by Functionality
• 8.1 Fillers and Diluents
• 8.2 Binders
• 8.3 Coating Agents
• 8.4 Disintegrants
• 8.5 Solubilizers and Emulsifiers
• 8.6 Lubricants and Glidants
• 8.7 Flavoring Agents and Sweeteners
• 8.8 Preservatives
• 8.9 Others
9. Global Market Analysis by Formulation
• 9.1 Oral (Tablets, Capsules, Liquids)
• 9.2 Parenteral
• 9.3 Topical
• 9.4 Others (Inhalation, Ophthalmic, Nasal)
10. Regional Analysis (Value, Volume, Capacity, 2021–2034)
• 10.1 North America (U.S., Canada, Mexico)
• 10.2 Europe (Germany, France, Italy, U.K., Spain, Switzerland, Ireland, Rest of Europe)
• 10.3 Asia Pacific (China, India, Japan, South Korea, Australia, Southeast Asia, Rest of Asia Pacific)
• 10.4 Latin America (Brazil, Argentina, Rest of Latin America)
• 10.5 Middle East and Africa (GCC, South Africa, Rest of Middle East and Africa)
11. Regulatory Landscape
• 11.1 Pharmacopoeial Standards (USP–NF, Ph. Eur., JP, IP)
• 11.2 Excipient GMP and Certification Schemes
• 11.3 Novel Excipient Review Initiatives
• 11.4 Elemental Impurities and Nitrosamine Risk Controls
12. Competitive Landscape
• 12.1 Market Structure and Concentration
• 12.2 Recent Mergers, Acquisitions and Divestitures
• 12.3 Epignosis Insights Competitive Assessment Framework (EICAF)
• 12.4 EICAF Scoring Method and Company Rankings
13. Company Profiles
• 13.1 Roquette (incl. former IFF Pharma Solutions)
• 13.2 BASF Pharma Solutions
• 13.3 Ashland
• 13.4 Evonik Health Care
• 13.5 DFE Pharma
• 13.6 Colorcon
• 13.7 JRS Pharma
• 13.8 MEGGLE
• 13.9 Merck KGaA
• 13.10 Shin-Etsu Chemical
• 13.11 Lubrizol
• 13.12 Croda
• 13.13 Gattefossé
• 13.14 SPI Pharma (incl. former Elementis Pharma)
• 13.15 Asahi Kasei
• 13.16 Kerry
• 13.17 Wacker Chemie
• 13.18 Avantor
• 13.19 Sigachi Industries
• 13.20 Ideal Cures
• Each profile: Company Overview, Excipient Portfolio, Manufacturing Footprint, Financial Snapshot, Recent Developments
14. Strategic Recommendations
• 14.1 For Excipient Manufacturers
• 14.2 For Pharmaceutical Formulators and Procurement Teams
• 14.3 For Investors
15. Appendix
• 15.1 List of Tables
• 15.2 List of Figures
• 15.3 Disclaimer